EXTH-84. Therapeutic Efficacy of the Characteristic Magnetic Field Signal of Paclitaxel for Glioblastoma Treatment

Glioblastoma (GBM) is the most common malignant tumor of the central nervous system. Despite advances in surgery, radiotherapy, chemotherapy, and targeted therapy, its 5-year survival rate remains very low at approximately 7.1%, and the median survival time is typically less than two years. Therefore, new therapeutic strategies are urgently needed. Low-frequency magnetic fields have been shown to inhibit tumor cell growth and proliferation and induce tumor cell death; however, identifying effective magnetic field parameters requires extensive exploration, greatly increasing time and experimental costs. Recent studies have found that biological agents or chemical drugs can generate characteristic magnetic signals, which can produce biological effects equivalent to those of the drugs themselves while overcoming therapeutic challenges such as the blood-brain barrier and tumor heterogeneity. In this study, we developed a superconducting quantum interference device based on stochastic resonance to successfully extract the magnetic signal of the classic chemotherapeutic agent paclitaxel. We comprehensively evaluated its effects on cell proliferation and apoptosis through in vitro assays, including CCK-8, flow cytometry, and immunofluorescence. Additionally, we verified its in vivo safety and antitumor efficacy by establishing a mouse glioma model. Experimental results demonstrated that multiple biological assays confirmed the inhibitory effect of paclitaxel’s characteristic magnetic signal on GBM was equivalent to that of paclitaxel itself, and its antitumor mechanism was highly similar to that of the parent drug. Moreover, animal experiments showed significant safety and the ability to cross the blood-brain barrier to achieve antitumor effects, significantly prolonging the survival of tumor-bearing mice. Our study indicates that applying paclitaxel’s unique magnetic signal may offer a new therapeutic strategy for GBM patients.